NuVasive (Nasdaq: NUVA ) is expected to report Q4 earnings on Feb. 26. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict NuVasive's revenues will expand 3.8% and EPS will drop -22.2%.
The average estimate for revenue is $155.8 million. On the bottom line, the average EPS estimate is $0.21.
Last quarter, NuVasive logged revenue of $148.4 million. GAAP reported sales were 12% higher than the prior-year quarter's $132.9 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.23. GAAP EPS were $0.05 for Q3 versus -$1.69 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 74.6%, 580 basis points worse than the prior-year quarter. Operating margin was 8.5%, 110 basis points better than the prior-year quarter. Net margin was 1.6%, 5,240 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $617.7 million. The average EPS estimate is $0.91.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 172 members out of 191 rating the stock outperform, and 19 members rating it underperform. Among 44 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 40 give NuVasive a green thumbs-up, and four give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on NuVasive is outperform, with an average price target of $26.70.
Is NuVasive the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.